NASDAQ:INVA Innoviva Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Innoviva Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.56 -0.04 (-0.34 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$11.46Now: $11.57▼$11.7950-Day Range$11.18MA: $12.55▼$13.9652-Week Range$7.58Now: $11.57▼$15.62Volume1.94 million shsAverage Volume790,933 shsMarket Capitalization$1.17 billionP/E Ratio5.61Dividend YieldN/ABeta0.9 ProfileChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Brisbane, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Innoviva. Previous Next 2.1 Community Rank Outperform VotesInnoviva has received 284 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInnoviva has received 377 “underperform” votes. (Add your “underperform” vote.)Community SentimentInnoviva has received 57.03% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote “Outperform” if you believe INVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.32% of the stock of Innoviva is held by insiders.Percentage Held by Institutions73.42% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Innoviva are expected to decrease by -32.20% in the coming year, from $1.77 to $1.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 5.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 18.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 5.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.48.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.87 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone650-238-9600Debt Debt-to-Equity Ratio0.77 Current Ratio92.39 Quick Ratio92.39Price-To-Earnings Trailing P/E Ratio5.61 Forward P/E Ratio6.53 P/E GrowthN/A Sales & Book Value Annual Sales$261.02 million Price / Sales4.49 Cash Flow$1.75 per share Price / Cash Flow6.59 Book Value$3.38 per share Price / Book3.42Profitability EPS (Most Recent Fiscal Year)$1.43 Net Income$157.29 million Net Margins76.28% Return on Equity59.83% Return on Assets29.73%Miscellaneous Employees6 Outstanding Shares101,392,000Market Cap$1.17 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $11.56 -0.04 (-0.34 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive INVA News and Ratings via Email Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. Innoviva (NASDAQ:INVA) Frequently Asked Questions How has Innoviva's stock been impacted by Coronavirus (COVID-19)? Innoviva's stock was trading at $12.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INVA shares have decreased by 3.9% and is now trading at $11.5650. View which stocks have been most impacted by COVID-19. When is Innoviva's next earnings date? Innoviva is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Innoviva. How were Innoviva's earnings last quarter? Innoviva Inc (NASDAQ:INVA) released its earnings results on Wednesday, July, 29th. The biotechnology company reported $0.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.32 by $0.37. The biotechnology company had revenue of $78.95 million for the quarter. Innoviva had a return on equity of 59.83% and a net margin of 76.28%. View Innoviva's earnings history. Are investors shorting Innoviva? Innoviva saw a increase in short interest in August. As of August 14th, there was short interest totaling 13,320,000 shares, an increase of 10.3% from the July 30th total of 12,080,000 shares. Based on an average trading volume of 704,700 shares, the short-interest ratio is presently 18.9 days. Currently, 19.3% of the shares of the stock are sold short. View Innoviva's Short Interest. Who are some of Innoviva's key competitors? Some companies that are related to Innoviva include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX) and Exelixis (EXEL). View all competitors. What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Pfizer (PFE), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Advanced Micro Devices (AMD), Opko Health (OPK) and Occidental Petroleum (OXY). Who are Innoviva's key executives? Innoviva's management team includes the following people: Mr. Geoffrey Hulme, Interim Principal Exec. Officer (Age 52)Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 50)Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VPDr. Kevin Kwok, Head of Talent Acquisition & Strategy What is Innoviva's stock symbol? Innoviva trades on the NASDAQ under the ticker symbol "INVA." Who are Innoviva's major shareholders? Innoviva's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.73%), LSV Asset Management (3.61%), First Eagle Investment Management LLC (2.03%), Goldman Sachs Group Inc. (1.76%), Man Group plc (1.20%) and Principal Financial Group Inc. (0.55%). Company insiders that own Innoviva stock include Geoffrey Hulme, George Bickerstaff, Innoviva, Inc and Marianne Zhen. View institutional ownership trends for Innoviva. Which institutional investors are selling Innoviva stock? INVA stock was sold by a variety of institutional investors in the last quarter, including Atom Investors LP, WINTON GROUP Ltd, Nuveen Asset Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, Man Group plc, State of Tennessee Treasury Department, Nisa Investment Advisors LLC, and Marshall Wace LLP. View insider buying and selling activity for Innoviva. Which institutional investors are buying Innoviva stock? INVA stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., First Eagle Investment Management LLC, Jefferies Group LLC, Denali Advisors LLC, Robeco Institutional Asset Management B.V., Canada Pension Plan Investment Board, AJO LP, and TD Asset Management Inc.. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme, George Bickerstaff, and Innoviva, Inc. View insider buying and selling activity for Innoviva. How do I buy shares of Innoviva? Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Innoviva's stock price today? One share of INVA stock can currently be purchased for approximately $11.57. How big of a company is Innoviva? Innoviva has a market capitalization of $1.17 billion and generates $261.02 million in revenue each year. The biotechnology company earns $157.29 million in net income (profit) each year or $1.43 on an earnings per share basis. Innoviva employs 6 workers across the globe. What is Innoviva's official website? The official website for Innoviva is www.inva.com. How can I contact Innoviva? Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
